Venture Capital Investors

Complement Therapeutics

Complement Therapeutics is a VC investing group that backs high-potential tech companies.

Venture Investor Overview

Contact Information

Background Information

Overview

Geographic atrophy (late dry age-related macular degeneration) is a chronic eye condition that affects millions -- and for which there is currently no available treatment. The disease is related to Complement System disorders. Through an extensive programme of translational research we have gained powerful new insights into the ways the Complement System works and how it is dysregulated in age-related macular degeneration. We are now using these insights to develop a portfolio of treatments for Complement-related diseases including age-related macular degeneration, each with a high unmet clinical need.

Profile

Social Media

Company News

Facebook

YouTube

Last Transaction

4/17/2023

Transaction History

Our records indicate that Complement Therapeutics invested in the VC transactions listed below. Dollar amounts are for the entire raise, which may include other investors.

Investor Contacts

Title

Name

Email & Social

Founder

Simon Clark

        

Chief Executive Officer

Rafiq Hasan

        

Chief Scientific Officer

Dennis Keefe

        

VP - Business Development

Mustafa Munye

        

Founder

Richard Unwin

        

Funds

No fund closings have been recorded for this company.

Portfolio Companies

Complement Therapeutics has invested in only one tech company, according to our database records. If we are missing a portfolio company, please let us know.

Browse more venture capital investors:

Compass Technology Partners | Complex China

Share this article

About Our Venture Capital Investor Database

Our data comes from VentureDeal.com, a market leader in private equity transaction data.

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary